Expansion of multiple CD4<sup>+</sup> T-cell lineages in lymphocytic variant hypereosinophilic syndrome.

Anderson, Charles F; Makiya, Michelle; Xiong, Knaunong; Penrod, Lori; Wetzler, Lauren; Ware, JeanAnne; Constantine, Gregory M; Khoury, Paneez et al. · J Allergy Clin Immunol · 2025

case_series · Level IV

Where this comes from

Abstract

Lymphocytic variant hypereosinophilic syndrome (LHES) is a rare disorder characterized by hypereosinophilia, the presence of phenotypically aberrant populations of T<sub>H</sub>2 lymphocytes, and varied clinical manifestations. Although disease pathogenesis has historically been attributed to IL-5-driven hypereosinophilia, response to eosinophil-lowering biologics is not universal, suggesting a more direct role for the aberrant lymphocyte population in disease pathogenesis. We sought to further delineate the surface phenotypes and cytokine profiles of the aberrant lymphocyte populations in patients with LHES. Multiparameter flow cytometry was used to analyze lymphocytes in whole blood and stored peripheral blood mononuclear cells from a cohort of 42 untreated and treated patients with LHES. Surface receptor profiling of the aberrant population in 22 untreated patients with LHES, including 8 patients with episodic angioedema with eosinophilia, confirmed prior data demonstrating that the aberrant CD4<sup>+</sup> T-cell populations in LHES have a T<sub>H</sub>2 memory phenotype. CCR8 was identified as a dominant surface marker, unaffected by sample processing or patient treatment status. Serum levels of CCL1, the ligand for CCR8, were increased in LHES patients compared to patients with other hypereosinophilic syndrome subtypes. Expanded populations of FoxP3<sup>+</sup>Helios<sup>+</sup>CCR8<sup>+</sup> regulatory T cells were identified in many patients with CD3<sup>lo</sup>CD4<sup>+</sup> LHES and correlated with the size of the CD3<sup>lo</sup>CD4<sup>+</sup> population. These data provide further evidence for direct involvement of the aberrant T-cell populations in disease pathogenesis in LHES and a rationale for further exploration of T-cell-directed therapies.

Medical subject headings